JP2003524592A5 - - Google Patents

Download PDF

Info

Publication number
JP2003524592A5
JP2003524592A5 JP2000557816A JP2000557816A JP2003524592A5 JP 2003524592 A5 JP2003524592 A5 JP 2003524592A5 JP 2000557816 A JP2000557816 A JP 2000557816A JP 2000557816 A JP2000557816 A JP 2000557816A JP 2003524592 A5 JP2003524592 A5 JP 2003524592A5
Authority
JP
Japan
Prior art keywords
coating
protective
protective coating
soluble
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000557816A
Other languages
English (en)
Other versions
JP2003524592A (ja
Filing date
Publication date
Priority claimed from US09/111,188 external-priority patent/US5968554A/en
Priority claimed from US09/338,716 external-priority patent/US6312728B1/en
Application filed filed Critical
Publication of JP2003524592A publication Critical patent/JP2003524592A/ja
Publication of JP2003524592A5 publication Critical patent/JP2003524592A5/ja
Pending legal-status Critical Current

Links

Description

低pHで溶解する保護コーティングは、胃液(pH約1.5−3.0)中で容易に溶け、当該治療剤の下層コーティングに対して保護効果を有する物質なら、どんな物質であっても良い。少なくとも、当該保護コーティングは、当該治療剤のコーティングに対する磨耗を防止する効果を有し、水の吸収を減らし、個々の投与形態間の付着を抑えるようなものである。当該保護コーティングに使用できる物質の代表例として、Methocel(登録商標)および水溶性である他のセルロース化合物および糖類が存在する。前にも述べたように、低pHで可溶な保護コーティングは本発明における投与形態から除外することができる。しかし当該投与形態には、当該保護コーティングもこれを含めることが好ましい。
JP2000557816A 1998-07-07 1999-06-25 持続放出薬物製剤 Pending JP2003524592A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09/111,188 US5968554A (en) 1998-07-07 1998-07-07 Sustained release pharmaceutical preparation
US09/111,188 1998-07-07
US09/338,716 1999-06-23
US09/338,716 US6312728B1 (en) 1998-07-07 1999-06-23 Sustained release pharmaceutical preparation
PCT/US1999/014204 WO2000001369A1 (en) 1998-07-07 1999-06-25 Sustained release pharmaceutical preparation

Publications (2)

Publication Number Publication Date
JP2003524592A JP2003524592A (ja) 2003-08-19
JP2003524592A5 true JP2003524592A5 (ja) 2006-01-05

Family

ID=26808709

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000557816A Pending JP2003524592A (ja) 1998-07-07 1999-06-25 持続放出薬物製剤

Country Status (10)

Country Link
US (1) US6312728B1 (ja)
EP (1) EP1094790B9 (ja)
JP (1) JP2003524592A (ja)
AT (1) ATE274344T1 (ja)
AU (1) AU5084299A (ja)
CA (1) CA2337046C (ja)
DE (1) DE69919713T2 (ja)
ES (1) ES2226412T3 (ja)
IL (1) IL140761A0 (ja)
WO (1) WO2000001369A1 (ja)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9803871D0 (sv) * 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
US20030068356A1 (en) * 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
US6572889B1 (en) 2002-03-07 2003-06-03 Noveon Ip Holdings Corp. Controlled release solid dosage carbamazepine formulations
US20040043067A1 (en) * 2002-06-19 2004-03-04 Salamone Joseph C. Fluorosiloxane matrix controlled diffusion drug delivery systems
MY142204A (en) 2002-07-25 2010-10-29 Pharmacia Corp Pramipexole once-daily dosage form
JP2006507298A (ja) * 2002-10-30 2006-03-02 ファルマシア コーポレーション 経口持続放出型錠剤、ならびにその製造法および使用法
US7988993B2 (en) 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
US20040253293A1 (en) * 2003-06-16 2004-12-16 Afshin Shafiee Rate controlled release of a pharmaceutical agent in a biodegradable device
WO2005030179A1 (en) * 2003-09-29 2005-04-07 Cj Corporation Sustained-release formulations
US7670624B2 (en) * 2004-01-29 2010-03-02 Astella Pharma Inc. Gastrointestinal-specific multiple drug release system
US7712288B2 (en) 2004-05-28 2010-05-11 Narayanan Ramasubramanian Unified ingestion package and process for patient compliance with prescribed medication regimen
US9592197B2 (en) * 2004-12-16 2017-03-14 Sovereign Pharmaceuticals, Llc Dosage form containing diphenhydramine and another drug
US20070003622A1 (en) * 2004-12-16 2007-01-04 Sovereign Pharmaceuticals, Ltd. Diphenhydramine containing dosage form
US20060034910A1 (en) * 2004-08-09 2006-02-16 Sanjay Patel Pharmaceutical composition for extended release of phenytoin sodium
CN101843597A (zh) 2004-08-13 2010-09-29 贝林格尔·英格海姆国际有限公司 包含普拉克索或其可药用盐的延长释放小球制剂、其制备方法及其用途
SI1781260T2 (sl) 2004-08-13 2014-08-29 Boehringer Ingelheim International Gmbh Tabletna formulacija s podaljšanim sproščanjem, ki vsebuje pramipeksol ali njegovo farmacevtsko sprejemljivo sol, postopek za izdelavo le-te in njena uporaba
US20060134175A1 (en) * 2004-12-22 2006-06-22 Stephen Bartels Drug eluting pharmaceutical delivery system for treatment of ocular disease and method of use
US7529255B2 (en) * 2005-04-21 2009-05-05 Microsoft Corporation Peer-to-peer multicasting using multiple transport protocols
WO2007095523A2 (en) 2006-02-13 2007-08-23 Vanda Pharmaceuticals, Inc. Stable dosage formulations of imidazolylalkyl-pyridines
JP5228359B2 (ja) * 2007-04-12 2013-07-03 ニプロ株式会社 主薬粒子及びその製造方法ならびに口腔内崩壊錠
EP2152250B1 (en) * 2007-05-07 2019-09-04 Evonik Röhm GmbH Solid dosage forms comprising an enteric coating with accelerated drug release
AU2008334932B2 (en) 2007-12-13 2014-05-22 Vanda Pharmaceuticals Inc. Method and composition for treating an alpha adrenoceptor-mediated condition
US8618134B2 (en) 2007-12-13 2013-12-31 Vanda Pharmaceuticals Inc. Method and composition for treating a serotonin receptor-mediated condition
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
US8663671B2 (en) * 2009-11-05 2014-03-04 Philip Morris Usa Inc. Methods and compositions for producing hydrogel capsules coated for low permeability and physical integrity
US8999393B1 (en) 2013-01-09 2015-04-07 Edgemont Pharmaceuticals Llc Sustained release formulations of lorazepam
KR20220128362A (ko) 2019-12-27 2022-09-20 에벨로 바이오사이언시즈, 인크. 박테리아 및 미생물 세포외 소포체를 함유하는 고체 투여 형태
WO2021146523A1 (en) 2020-01-17 2021-07-22 Evelo Biosciences, Inc. Solid dosage forms with improved disintegration profiles
EP4135670A1 (en) 2020-04-17 2023-02-22 Evelo Biosciences, Inc. Solid dosage forms with improved disintegration profiles
AU2021342481A1 (en) 2020-09-18 2023-05-04 Evelo Biosciences, Inc. Solid dosage forms of bacteria
KR20230127985A (ko) 2020-10-29 2023-09-01 에벨로 바이오사이언시즈, 인크. 스피룰리나 성분을 포함하는 조성물
EP4259806A1 (en) 2020-12-14 2023-10-18 Evelo Biosciences, Inc. Extracellular vesicle preparations
EP4267154A1 (en) 2020-12-22 2023-11-01 Evelo Biosciences, Inc. Compositions comprising animal hemoglobin
KR20230137968A (ko) 2021-01-26 2023-10-05 에벨로 바이오사이언시즈, 인크. 프레보텔라 세포외 소포체 제제
EP4297762A1 (en) 2021-02-26 2024-01-03 Evelo Biosciences, Inc. Compositions and methods for reducing cytokine expression
TW202302125A (zh) 2021-03-05 2023-01-16 美商艾弗洛生物科技股份有限公司 固體劑型
TW202304415A (zh) 2021-04-08 2023-02-01 美商艾弗洛生物科技股份有限公司 含有細菌的藥物製劑
WO2022221183A1 (en) 2021-04-12 2022-10-20 Evelo Biosciences, Inc. Fournierella extracellular vesicle preparations
WO2022251166A2 (en) 2021-05-25 2022-12-01 Evelo Biosciences, Inc. Bacterial compositions comprising soy hemoglobin
WO2023049268A1 (en) 2021-09-24 2023-03-30 Evelo Biosciences, Inc. Solid dosage forms containing bacteria and microbial extracellular vesicles
WO2023114293A1 (en) 2021-12-14 2023-06-22 Evelo Biosciences, Inc. Extracellular vesicle assays
WO2023114295A1 (en) 2021-12-14 2023-06-22 Evelo Biosciences, Inc. Veillonella parvula bacteria extracellular vesicle preparations
WO2023114300A1 (en) 2021-12-14 2023-06-22 Evelo Biosciences, Inc. Fournierella massiliensis bacteria extracellular vesicle preparations
WO2023146843A1 (en) 2022-01-25 2023-08-03 Evelo Biosciences, Inc. Extracellular vesicle compositions and methods of use
WO2023183396A1 (en) 2022-03-22 2023-09-28 Evelo Biosciences, Inc. Compositions and methods of treating inflammation using prevotella histicola
WO2023200837A1 (en) 2022-04-13 2023-10-19 Evelo Biosciences, Inc. Compositions and methods of treating inflammation using prevotella histicola
WO2023239728A1 (en) 2022-06-07 2023-12-14 Evelo Biosciences, Inc. Compositions and methods of treating inflammation using prevotella histicola extracellular vesicles
WO2024102226A1 (en) 2022-10-14 2024-05-16 Evelo Biosciences, Inc. Methods for assaying drug substances and drug products by using cell lines with nf-kb- inducible reporter genes

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994260A (en) 1982-05-28 1991-02-19 Astra Lakemedel Aktiebolag Pharmaceutical mixture
US5238686A (en) 1986-03-27 1993-08-24 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
US4968508A (en) 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
US5540945A (en) * 1989-05-11 1996-07-30 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical preparations for oral administration that are adapted to release the drug at appropriate sites in the intestines
ES2064564T3 (es) * 1989-09-21 1995-02-01 American Cyanamid Co Sistema de liberacion pulsatil de dosis unitaria diaria de minociclina.
ATE119766T1 (de) * 1989-10-26 1995-04-15 Nippon Shinyaku Co Ltd Zubereitung für den magen.
US5229131A (en) 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
US5188836A (en) 1990-07-27 1993-02-23 Warner-Lambert Company Sustained release formulations
US5102668A (en) 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
US5286493A (en) 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
DE19630035A1 (de) * 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
US5885616A (en) * 1997-08-18 1999-03-23 Impax Pharmaceuticals, Inc. Sustained release drug delivery system suitable for oral administration
US5968554A (en) * 1998-07-07 1999-10-19 Cascade Development, Inc. A Subsidiary Of Cardinal Health, Inc. Sustained release pharmaceutical preparation

Similar Documents

Publication Publication Date Title
JP2003524592A5 (ja)
CA2213996A1 (en) Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an antacid agent or alginate
HUP0103883A2 (hu) Új, késleltetett felszabadulású, orális készítmények
CA2396159A1 (en) Novel substituted benzimidazole dosage forms and method of using same
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
CA2323680A1 (en) Orally disintegrable tablets
JP2005516946A5 (ja)
NO20015782D0 (no) Kostblanding eller farmasöytisk sammensetning til anvendelse for forebyggelse eller behandling av hyperoksaluri
HUP0003691A2 (hu) Gyorsan széteső, többrészes tabletták
MA26516A1 (fr) Tartrate d'un dipeptide substitue, procede pour sa preparation et compositions pharmaceutiques le contenant.
CA2348451A1 (en) Dosage forms containing taste masked active agents
DK1183014T3 (da) Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse
CA2213987A1 (en) Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a nsaid
EP1698672A3 (de) Beschichtungsmasse mit Biozidmikrokapseln
CA2457029A1 (en) Breath freshening film
HUP0203168A2 (hu) Készítmények nyálkahártyán át történő beadásra
ATE473006T1 (de) Beschichtete teilchenförmige cefuroximeaxetil- zusammensetzungen
HUP0105313A3 (en) Potassium salt of (s)-omeprazole, process for its preparation and pharmaceutical composition containing the same and its use
CA2463030A1 (en) Water-soluble pouches
CA2164776A1 (en) Pharmaceutical, orally applicable composition
EP1181931A3 (en) Intraoral adhesive preparation
JP2002127601A5 (ja)
NO20021640D0 (no) Sammensetning til forebygging og/eller behandling av kretslöpsykdommer som omfatter derivater av L-karnitin ogekstrakter av Ginko Biloba
DE60026481D1 (de) Wässriges filmbildendes Überzugsmittel und oral anzuwendende feste Arzneizubereitung
RU93048335A (ru) Оральная лекарственная форма, материал для оболочки